FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease

Eisai announced FDA approval of a supplemental Biologics License Application (sBLA) for a once-weekly lecanemab subcutaneous injection. The approval expands the administration schedule and potentially improves patient convenience and uptake versus prior dosing regimens. This regulatory milestone is a clear positive catalyst for BioArctic’s lecanemab-related program.

Analysis

Eisai announced FDA approval of a supplemental Biologics License Application (sBLA) for a once-weekly lecanemab subcutaneous injection. The approval expands the administration schedule and potentially improves patient convenience and uptake versus prior dosing regimens. This regulatory milestone is a clear positive catalyst for BioArctic’s lecanemab-related program.